Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECT OF INCREASING DOSES OF BETA-AGONISTS ON SPIROMETRIC PARAMETERS, EXERCISE CAPACITY, AND QUALITY-OF-LIFE IN PATIENTS WITH CHRONIC AIR-FLOW LIMITATION
Autore:
JAESCHKE R; GUYATT GH; WILLAN A; COOK D; HARPER S; MORRIS J; RAMSDALE H; HADDON R; NEWHOUSE M;
Indirizzi:
ST JOSEPHS HOSP,FONTBONNE BLDG,50 CHARLTON AV E HAMILTON L8N 4A6 ON CANADA MCMASTER UNIV,DEPT MED HAMILTON ON CANADA MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT HAMILTON ON CANADA ASTRA PHARMA INC MISSISSAUGA ON CANADA
Titolo Testata:
Thorax
fascicolo: 5, volume: 49, anno: 1994,
pagine: 479 - 484
SICI:
0040-6376(1994)49:5<479:EOIDOB>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
AIR-FLOW LIMITATION; OBSTRUCTIVE PULMONARY-DISEASE; SHORT-TERM VARIABILITY; CHRONIC-BRONCHITIS; AIRWAYS OBSTRUCTION; INHALED TERBUTALINE; CLINICAL USEFULNESS; INDIVIDUAL PATIENTS; RANDOMIZED TRIALS; SALBUTAMOL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
41
Recensione:
Indirizzi per estratti:
Citazione:
R. Jaeschke et al., "EFFECT OF INCREASING DOSES OF BETA-AGONISTS ON SPIROMETRIC PARAMETERS, EXERCISE CAPACITY, AND QUALITY-OF-LIFE IN PATIENTS WITH CHRONIC AIR-FLOW LIMITATION", Thorax, 49(5), 1994, pp. 479-484

Abstract

Background - A study was undertaken to determine the impact of different doses of inhaled terbutaline on peak flow rates, spirometric parameters, functional exercise capacity, and quality of life in patients with chronic airflow limitation. Methods - A double blind, randomised, placebo controlled, multiple crossover trial was conducted with treatment periods of one week. Patients with a clinical diagnosis of chronicairflow limitation and FEV(1) below 70% predicted after administration of bronchodilator were recruited from secondary care respiratory practices, and the effect of 500, 1000, and 1500 mu g inhaled terbutalinefour times daily on spirometric parameters (FEV(1), FVC), maximum inspiratory pressures, six minute walking distance, and health-related quality of life (Chronic Respiratory Disease Questionnaire, Quality of Well Being, Standard Gamble) was measured. Results - Twenty five patients completed the trial. Peak flow rates and FEV, showed statistically significant but clinically trivial improvement on the higher drug doses. Results of maximum inspiratory pressure measurements, walk test distance, and quality of life measures showed minimal differences on the different dosages, and none of the differences approached conventionalstatistical significance, Conclusions - Regular use of beta agonists in doses higher than two puffs four times a day is very unlikely to provide additional functional or symptomatic benefit to patients with chronic airflow limitation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 19:51:12